Observational studyScientific reports2025
Changes in blood concentration of tranexamic acid in dialysis and non-dialysis patients undergoing cardiac surgery: a prospective observational cohort study.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmacokinetics of tranexamic acid (TXA), used during cardiopulmonary bypass (CPB) surgery, in patients receiving maintenance hemodialysis remain unclear. This prospective study compared serum tranexamic acid (TXA) concentrations following bolus administration and subsequent intensive care unit (ICU) admission in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB), including those receiving maintenance hemodialysis and those not on dialysis. Participants received two TXA boluses: 1000 mg (500 mg for patients receiving hemodialysis) at procedure initiation and another 1000 mg (500 mg for patients receiving hemodialysis) after CPB withdrawal. Blood samples were collected at 30, 60, and 120 min, and after CPB weaning after the first dose; following the second dose; upon ICU admission; and at 4, 8, and 12 h post-ICU admission to measure TXA concentrations. A renal function-based simulation model was developed to optimize TXA dosing. Among 82 patients (74 without dialysis and 8 receiving hemodialysis), serum TXA concentrations were similar between groups until ICU admission. Following CPB withdrawal, patients receiving hemodialysis exhibited higher TXA concentrations than non-dialysis patients, despite receiving only half the total dose. TXA concentrations remained significantly higher in hemodialysis patients after ICU admission. Bolus administration effectively maintained antifibrinolytic TXA levels (> 10 µg/mL). The renal function-based model guides optimal TXA dosing strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.